Bluejay Diagnostics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $249,040 | — |
| Gross profit | — | — | — | $48,911 | — |
| Operating income | -$7.0M | -$7.2M | -$10.3M | -$9.3M | -$3.2M |
| Operating expenses | $7.0M | $7.2M | $10.3M | $9.4M | $3.2M |
| Cost of revenue | — | — | — | $200,129 | — |
| Cash from operations | -$6.1M | -$7.8M | -$8.3M | -$7.7M | -$4.4M |
| Capital expenditure | $173,735 | $306,783 | $704,166 | $1.2M | $23,947 |
| Free cash flow | -$6.2M | -$8.1M | -$9.0M | -$8.9M | -$4.4M |
| Impairments | $42,937 | $3,411 | $1,787 | $237,309 | — |
| Total assets | $7.1M | $6.7M | $4.9M | $13.5M | $21.0M |
| Total liabilities | $1.1M | $927,924 | $2.0M | $2.0M | $637,162 |
Shares outstanding 1.0M · Free float 93.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.